IP Library Granted Patent US 9,512,168
Granted Patent B2
US 9,512,168 · App. 14/299,671 · Granted Dec 6, 2016

Compound, composition and method for treating and/or ameoliorating kidney disease

Inventors: Cheng-Po Huang (Hsinchu, TW); Teng-Hai Chen (Tainan, TW); Kuang Dee Chen (Chiayi, TW); Chun-Tao Su (Taipei, TW)
C07J9/005A61K31/00A61K31/575
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,512,168
App. No.
14/299,671
Granted
Dec 6, 2016
Kind
B2
Abstract

Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E 2 (LAE 2 ), lucidenic acid A (LAA), and lucidenic acid D 2 (LAD 2 ).

Claims (8)

1. A method of improving kidney function in a subject having a kidney inflammation or acute kidney injury comprising administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg, to reduce the levels of blood urine nitrogen (BUN), creatinine (CRE), and urine protein, or to increase the glomerular filtration rate (GFR) of the subject, as compared to those of the subject before administering the compound of formula (I),

2. The method of claim 1 , further comprising administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid B (LAB), lucidenic acid N (LAN), lucidenic acid E 2 (LAE 2 ), lucidenic acid A (LAA), and lucidenic acid D 2 (LAD 2 ).

3. The method of claim 2 , wherein the LAC is administered to the subject in a dose of about 1 to 10 mg/Kg.

4. The method of claim 2 , wherein the LAA and LAD 2 are respectively administered to the subject in a dose of about 2.5 to 25 mg/Kg.

5. The method of claim 2 , wherein the LAE 2 is administered to the subject in a dose of about 1.5 to 15 mg/Kg.

6. The method of claim 2 , wherein the LAN and LAB are respectively administered to the subject in a dose of about 0.85 to 8.5 mg/Kg.

7. The method of claim 1 , wherein the subject is a human.

8. The method of claim 1 , wherein the subject has acute kidney injury or chronic kidney inflammation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2025
From: TRINEO BIOTECHNOLOGY CO., LTD.
To: YUNG KIEN INDUSTRIAL CORP.
Reel/Frame 072384/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2016
From: HUANG, CHENG-PO; CHEN, TENG-HAI; CHEN, KUANG DEE; SU, CHUN-TAO
To: TRINEO BIOTECHNOLOGY CO. LTD.
Reel/Frame 038647/0385 →
Continuity (1)
Related Publication 20150353595A1 · Dec 10, 2015